In patients with left ventricular assist device support and aspirin allergy, the choice of effective antiplatelet strategy remains a challenge. We compared the antithrombotic effect of clopidogrel vs ticagrelor in an LVAD patient with aspirin allergy by using a modified protocol of the thrombin generation test, accounting selectively for the platelet contribution on thrombin generation. Our results demonstrate enhanced antithrombotic efficacy offered by ticagrelor. Consistent with experimental results, the patient has passed more than 300 days without thromboembolic complications. This study provides additional mechanistic rationale supporting clinical evidence and opens the perspective to identify individual poor responsiveness to drugs by specifically evaluating drug-mediated platelet function.
Which Antiplatelet Therapy in Patients With Left Ventricular Assist Device and Aspirin Allergy? / Consolo, Filippo; Pozzi, Loris; Sferrazza, Giulia; Della Valle, Patrizia; D'Angelo, Armando; Slepian, Marvin J.; Pappalardo, Federico. - In: ANNALS OF THORACIC SURGERY. - ISSN 0003-4975. - 105:2(2018), pp. e47-e49. [10.1016/j.athoracsur.2017.09.022]
Which Antiplatelet Therapy in Patients With Left Ventricular Assist Device and Aspirin Allergy?
Consolo, Filippo;Pappalardo, Federico
2018-01-01
Abstract
In patients with left ventricular assist device support and aspirin allergy, the choice of effective antiplatelet strategy remains a challenge. We compared the antithrombotic effect of clopidogrel vs ticagrelor in an LVAD patient with aspirin allergy by using a modified protocol of the thrombin generation test, accounting selectively for the platelet contribution on thrombin generation. Our results demonstrate enhanced antithrombotic efficacy offered by ticagrelor. Consistent with experimental results, the patient has passed more than 300 days without thromboembolic complications. This study provides additional mechanistic rationale supporting clinical evidence and opens the perspective to identify individual poor responsiveness to drugs by specifically evaluating drug-mediated platelet function.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.